Introduction {#s1}
============

Overactive bladder (OAB) is defined as a series of symptoms ([@B2]; [@B50]), including urinary urgency (usually accompanied by frequency and nocturia) and urinary incontinence (UI) in the absence of urinary tract infection (UTI) or other obvious pathology, according to the statement established by International Continence Society. The classification of OAB ([@B48]; [@B32]) are generally considered two types: neurogenic detrusor overactivity (NDO) and idiopathic overactive bladder (IOAB). Almost 16.9% women suffer UI caused by OAB in the United States, which means that this disease has become a considerable common health issue with significant effects on women mentally and physically, of which mainly on account of urgency UI ([@B16]).

For management of UI in OAB patients, anticholinergic medicine is currently recommended as the first-line therapy ([@B19]). Nevertheless, the anticholinergic medicine is increasingly inappropriate for long-term therapy of NDO and IOAB, which is reflected in the unsatisfied effect and potential complications such as vesicoureteral reflux and even renal failure ([@B33]; [@B4]), and also the high socioeconomic cost is considerable. Therefore, meta-analyses ([@B11]; [@B34]; [@B12]; [@B49]; [@B51]; [@B52]; [@B8]; [@B23]) evaluating the therapeutic effect of botulinum toxin A (BTX-A) on UI in OAB patients have increased as well as the relevant RCTs in recent years, in which the BTX-A demonstrated a satisfied clinical benefit. ([@B18]; [@B29]; [@B31]; [@B39]; [@B40]; [@B45]; [@B44]) Furthermore, the BTX-A is recommended for management of UI in OAB patient by the American Urological Association (AUA) guidelines ([@B22]), and the other interventions consist of education and behavior therapies. Nevertheless, the effect and safety of BTX-A is still controversial, furthermore, the clinical outcomes by different dosages also remains blank.

Therefore, we performed the systemic review and meta-analysis to evaluate the effect and safety of BTX-A at different dosages for the management of UI in patients with NDO and IOAB.

Methods {#s2}
=======

This systemic review and meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PRISMA) ([@B36]) and Cochrane Collaboration's systematic review framework ([@B26]).

Search Strategy {#s3}
===============

The Ovid MEDLINE, Ovid EMbase, and the Cochrane Central Register of Controlled Trials (CENTRAL), China National Knowledge Internet (CNKI), and WanFang databases were searched between 1964 to September 31, 2018. All database were searched to identify relevant randomized controlled trials (RCTs) that investigated the clinical benefit of BTX-A for management of UI in patients with NDO and IOAB. All search strategy is described in [**Supplementary Method 1**](#SM1){ref-type="supplementary-material"}.

Inclusion Criteria and Exclusion Criteria {#s4}
=========================================

RCTs were identified if the following criteria were met: (1) the patients with NDO or IOAB were confirmed; (2) patients \>18 year; (3) studies compared BTX-A with placebo or BTX-A at different dosages, which reported in English and Chinese.

Studies were excluded for the following reasons: (1) stress incontinence; (2) duplicate studies; (3) for continuous outcomes, the standard deviations (SD) was still missing after contacting with the authors; (4) evaluated the clinical benefit of different injection sites only; (5) follow-up period was less than 1 week.

Data Extraction {#s5}
===============

After independently reviewing the included studies by two reviewers (Hui-Yun Gu and Shuang Li), all following information were extracted: (1) first author, published year, regions, number of female patients, mean age, etiology of UI, and other basic disease; (2) the events, mean and SD of outcomes; (3) the effect outcomes and events in different time periods (2 weeks, 6 weeks, and 12 weeks) including UI episodes per week, maximum detrusor pressure (MDP), detrusor compliance (DC), and post void residual (PVR). The adverse events including urinary tract infections (UTI), urinary retention, hematuria, muscle weakness, and PVR-related catheterization were only recorded the events after follow-up without separately extracted according to different periods. The outcomes were expressed as two observation periods: short-term (≤12 weeks) and long-term (\>12 weeks).

Quality of Included Studies and Risk of Bias {#s6}
============================================

For evaluating the risk of bias in RCTs, the Cochrane Collaboration's tool ([@B25]) was performed by two independent reviewers (Hui-Yun Gu and Shuang Li), which considers seven domains including adequacy of blinding of participants, sequence generation, allocation concealment, blinding of outcome assessment, selective outcome reporting, incomplete outcome data, and other potential sources of bias, in each item was graded as "high risk", "low risk", or "unclear".

Statistical Analysis {#s7}
====================

Dichotomous outcomes were expressed as the relative risk (RR) with 95% confidence interval (CI) ([@B13]; [@B26]), and continuous outcomes were expressed as mean difference (MD) ([@B26]) with 95% CI. Both of them was bounded by P \<0.05 for statistical significance. Forest plot was carried out to summarize the outcomes. Heterogeneity was tested using I2 tests ([@B35]), in which the significance level was set to P\< 0.1. I^2^ statistic provides an estimate of the percentage of inconsistency thought to be due to chance ([@B27]). Initial analyses were performed using a fixed-effects model when I^2^\< 40%, the random model was performed when I^2^\> 40%.

The different dosages and types of IOAB and NDO were performed by subgroup analyses. All statistical analyses were performed using the Stata software (Versions, 12.0).

Results {#s8}
=======

Characteristics and Risk of Bias of Eligible Studies {#s8_1}
----------------------------------------------------

A total of 527 RCTs were initially identified, in which 86 studies were eliminated due to duplicates, then 441 studies were excluded in preliminary screening, therefore, only 53 articles were independently read in full text filtering. Ultimately, 34 studies were excluded ([**Supplementary Method 2**](#SM1){ref-type="supplementary-material"}), and a total of 19 articles ([@B46]; [@B43]; [@B5]; [@B9]; [@B15]; [@B3]; [@B10]; [@B24]; [@B42]; [@B14]; [@B21]; [@B6]; [@B20]; [@B28]; [@B37]; [@B41]; [@B7]; [@B47]; [@B1]) were included in this meta-analysis ([**Figure 1**](#f1){ref-type="fig"}).

![A flow diagram of the study selection process.](fphar-10-01618-g001){#f1}

Overall, 19 RCTs ([@B46]; [@B43]; [@B5]; [@B9]; [@B15]; [@B3]; [@B10]; [@B24]; [@B42]; [@B14]; [@B21]; [@B6]; [@B20]; [@B28]; [@B37]; [@B41]; [@B7]; [@B47]; [@B1]) comprised 5,596 participants who were diagnosed as IOAB or NDO with UI were included in this study. Eight RCTs with 2,097 patients in NDO, and the remaining 11 RCTs comprised 3,499 IOAB patients were treated with one of these two interventions: BTX-A or placebo. The characteristics of included studies were presented in [**Table 1**](#T1){ref-type="table"}.

###### 

Characteristics of individual study.

  Study        Year   Region         No. of patients (female)   Ages Mean(SD)                        Design                      Classification of urinary incontinence   Basic diseases    Intervention                                                                                                                                             Follow-up (weeks)
  ------------ ------ -------------- -------------------------- ------------------------------------ --------------------------- ---------------------------------------- ----------------- -------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------
  Schurch      2005   Switzerland    59(23)                     41                                   Randomized, doubled-blind   NDO                                      MS:6, SCI:53      Group 1: BTX-A 300U (19); Group 2: BTX-A 200U (19); Group 3: Placebo (21)                                                                                6
  Sahai        2007   UK             34(19)                     49.8, 50.8                           Randomized, doubled-blind   IOAB                                     NA                Group 1: BTX-A 200U (16); Group 2: Placebo (18)                                                                                                          NA
  Brubaker     2008   USA            43                         64.7(14.5), 69.2(13.5)               Randomized, doubled-blind   IOAB                                     NA                Group 1: BTX-A 200U (28); Group 2: Placebo (15)                                                                                                          NA
  Cohen        2009   USA            44                         NA                                   Randomized, doubled-blind   IOAB                                     NA                Group 1: BTX-A 150U (22); Group 2: BTX-A 100U (22)                                                                                                       NA
  Dmochowski   2010   USA            313(288)                   58.8                                 Randomized, doubled-blind   IOAB                                     NA                Group 1: BTX-A 50U (56); Group 2: BTX-A 100U (55); Group 3: BTX-A 150U (50); Group 4: BTX-A 200U (52); Group 5: BTX-A 300U (55); Group 6: Placebo (43)   NA
  Rovner       2011   USA            313(288)                   58.8                                 Randomized, doubled-blind   IOAB                                     NA                Group 1: BTX-A 50U (57); Group 2: BTX-A 100U (54); Group 3: BTX-A 150U (49); Group 4: BTX-A 200U (53); Group 5: BTX-A 300U (56); Group 6: Placebo (44)   12, 36
  Cruz         2011   Portugal       275(155)                   46(13.1), 44.4(13.9), 46.9(13.4)     Randomized, doubled-blind   NDO                                      MS:154, SCI:121   Group 1: BTX-A 200U (92); Group 2: BTX-A 300U (91); Group 3: Placebo (92)                                                                                2, 6, 12
  Herschorn    2011   Canada         57(23)                     42.8                                 Randomized, doubled-blind   NDO                                      MS:19, SCI:38     Group 1: BTX-A 300U (28); Group 2: Placebo (29)                                                                                                          NA
  Altaweel     2011   Saudi Arabia   22                         NA                                   Randomized, doubled-blind   IOAB                                     NA                Group 1: BTX-A 200U (11); Group 2: BTX-A 100U (11)                                                                                                       NA
  Denys        2012   France         199(87)                    62.3, 61.7                           Randomized, doubled-blind   IOAB                                     NA                Group 1: BTX-A 50U (23); Group 2: BTX-A 100U (23); Group 3: BTX-A 150U (30); Group 4: Placebo (31)                                                       12
  Ginsberg     2012   USA            416(245)                   46(13)                               Randomized, doubled-blind   NDO                                      MS:227, SCI:189   Group 1: BTX-A 200U (135); Group 2: BTX-A 300U (127); Group 3: Placebo (145)                                                                             6
  Rovner       2013   USA            691(400)                   45.9, 45.6, 46.2                     Randomized, doubled-blind   NDO                                      MS:103, SCI:138   Group 1: BTX-A 200U (227); Group 2: BTX-A 300U (223); Group 3: Placebo (241)                                                                             6
  Nitti        2013   USA            557(497)                   61.7(12.7), 61(13.1)                 Randomized, doubled-blind   IOAB                                     NA                Group 1: BTX-A 100U (278); Group 2: Placebo (272)                                                                                                        12
  Kennelly     2013   USA            387(233)                   46.4                                 Randomized, doubled-blind   NDO                                      SCI, MS           Group 1: BTX-A 300U (185); Group 2: BTX-A 200U (202)                                                                                                     6
  Ginsberg     2013   USA            381(311)                   49.7(12.1), 49.9(10.7), 50.2(10.7)   Randomized, doubled-blind   NDO                                      MS:381, SCI:310   Group 1: BTX-A 200U(227); Group 2: BTX-A 300U(223); Group 3: Placebo (241)                                                                               6
  Chapple      2013   UK             548(473)                   59.5(15.5), 59.2(14.1)               Randomized, doubled-blind   IOAB                                     NA                Group 1: BTX-A 100U (277); Group 2: Placebo (271)                                                                                                        NA
  Sievert      2014   Germany        1105(970)                  60.6(14.2), 60.1(13.6)               Randomized, doubled-blind   IOAB                                     NA                Group 1: BTX-A 100U (557); Group 2: Placebo (548)                                                                                                        NA
  Chen         2014   Taiwan         72(29)                     41.5                                 Randomized, doubled-blind   NDO                                      SCI               Group 1: BTX-A 300U (34); Group 2: BTX-A 200U (38)                                                                                                       NA
  Abdelwahab   2015   Egypt          80(63)                     31.35, 30.22                         Randomized, doubled-blind   IOAB                                     NA                Group 1: BTX-A 100U (40); Group 2: BTX-A 200U (40)                                                                                                       12, 36

BTX-A, Botulinum toxin A; NDO, Neurogenic detrusor overactivity; IOAB, Idiopathic overactive bladder; MS, Multiple sclerosis; SCI, Spinal cord injury; NA, Not available.

The risk of bias in eligible studies was assessed by two independent authors (Hui-Yun Gu and Shuang Li) using the Cochrane Collaboration tool, and found that the 19 included RCTs were all graded as high-quality studies ([**Table 2**](#T2){ref-type="table"}).

###### 

The risk of bias in the included studies.

  Authors      Year   Random sequence generation   Allocation concealment   Blinding of participants and personnel   Blinding of outcome assessment   Incomplete outcome data   Selective reporting   Other bias
  ------------ ------ ---------------------------- ------------------------ ---------------------------------------- -------------------------------- ------------------------- --------------------- ------------
  Schurch      2005   Low                          Low                      Low                                      Low                              Low                       Low                   Unclear
  Sahai        2007   Low                          Low                      Low                                      Low                              Unclear                   Low                   Unclear
  Brubaker     2008   Unclear                      Unclear                  Low                                      Unclear                          Low                       Low                   Unclear
  Cohen        2009   Low                          Low                      Low                                      Unclear                          Low                       Low                   Unclear
  Dmochowski   2010   Low                          Unclear                  Low                                      Low                              Low                       Low                   Unclear
  Rovner       2011   Low                          Low                      Unclear                                  Low                              Low                       Low                   Unclear
  Cruz         2011   Low                          Low                      Low                                      Low                              Low                       Low                   Unclear
  Herschorn    2011   Low                          Low                      Low                                      Low                              Low                       Low                   Unclear
  Altaweel     2011   Low                          Low                      Low                                      Low                              Low                       Low                   Unclear
  Denys        2012   Low                          Unclear                  Low                                      Low                              Low                       Low                   Unclear
  Ginsberg     2012   Low                          Low                      Low                                      Low                              Low                       Low                   Unclear
  Rovner       2013   Low                          Low                      Low                                      Low                              Low                       Low                   Unclear
  Nitti        2013   Low                          Low                      Unclear                                  Low                              Low                       Low                   Unclear
  Kennelly     2013   Low                          Low                      Low                                      Low                              Low                       Low                   Unclear
  Ginsberg     2013   Low                          Low                      Low                                      Low                              Low                       Low                   Unclear
  Chapple      2013   Low                          Low                      Low                                      Unclear                          Low                       Low                   Unclear
  Sievert      2014   Unclear                      Low                      Low                                      Unclear                          Low                       Low                   Unclear
  Chen         2014   Low                          Low                      Low                                      Unclear                          Low                       Low                   Unclear
  Abdelwahab   2015   Low                          Unclear                  Low                                      Unclear                          Low                       Low                   Unclear

Outcomes {#s8_2}
--------

All the results of following outcomes for NDO and IOAB patients were shown in [**Table 3**](#T3){ref-type="table"} and [**Table 4**](#T4){ref-type="table"}, respectively.

###### 

Summary of results with different dosage at different observation points for NDO.

  Outcomes                                             Number of RCTs   MD/RR    95%CI            I^2^ (%)   P for I^2^
  ---------------------------------------------------- ---------------- -------- ---------------- ---------- ------------
  **Episodes of Urinary Incontinence (UI) per Week**                                                         
  **2 weeks**                                                                                                
  BTX-A 200U VS. Placebo                               1                -9.1     -14.10, -4.10    NA         NA
  BTX-A 300U VS. Placebo                               1                -6.1     -12.54, 0.34     NA         NA
  BTX-A 300U VS. 200U                                  1                3        -3.30, 9.30      NA         NA
  **6 weeks**                                                                                                
  BTX-A 200U VS. Placebo                               3                -10.72   -13.40, -8.04    0          0.626
  BTX-A 300U VS. Placebo                               3                -11.42   -13.91, -8.93    50         0.135
  BTX-A 300U VS. 200U                                  4                -0.38    -2.60, 1.84      0          0.765
  **12 weeks**                                                                                               
  BTX-A 200U VS. Placebo                               1                -8.5     -14.46, -2.54    NA         NA
  BTX-A 300U VS. Placebo                               1                -7.8     -13.73, -1.87    NA         NA
  BTX-A 300U VS. 200U                                  1                0.7      -4.73, 6.13      NA         NA
  **Maximum Detrusor Pressure (MDP)**                                                                        
  **6 weeks**                                                                                                
  BTX-A 200U VS. Placebo                               5                -33.01   -37.75, -28.27   0          0.998
  BTX-A 300U VS. Placebo                               5                -31.31   -35.79, -26.84   0          0.679
  BTX-A 300U VS. 200U                                  6                1.16     -3.29, 5.60      0          0.831
  **Detrusor compliance (DC)**                                                                               
  **6 weeks**                                                                                                
  BTX-A 200U VS. Placebo                               2                66.29    44.24, 88.34     0          0.837
  BTX-A 300U VS. Placebo                               2                56.51    35.00, 78.03     0          0.910
  BTX-A 300U VS. 200U                                  2                -9.79    -35.00, 15.42    0          0.965
  **Post void residual (PVR)**                                                                               
  **2 weeks**                                                                                                
  BTX-A 200U VS. Placebo                               2                93.87    63.91, 123.84    0          0.887
  BTX-A 300U VS. Placebo                               2                178.22   138.50, 217.95   0          0.751
  BTX-A 300U VS. 200U                                  2                84.13    35.74, 132.51    0          0.727
  **Adverse Events\***                                                                                       
  **Urinary tract infections (UTI)**                                                                         
  BTX-A 200U VS. Placebo                               5                1.44     1.27, 1.62       0          0.974
  BTX-A 300U VS. Placebo                               6                1.51     1.35, 1.70       0          0.720
  BTX-A 300U VS. 200U                                  6                1.07     0.97, 1.18       0          0.909
  **Urinary retention**                                                                                      
  BTX-A 200U VS. Placebo                               4                5.85     3.84, 8.91       0          1.000
  BTX-A 300U VS. Placebo                               4                6.78     4.46, 10.30      0          0.872
  BTX-A 300U VS. 200U                                  4                1.16     0.95, 1.43       0          0.438
  **Muscle weakness**                                                                                        
  BTX-A 200U VS. Placebo                               3                1.53     0.76, 3.06       69.9       0.036
  BTX-A 300U VS. Placebo                               4                3.01     1.50, 6.02       0          0.910
  BTX-A 300U VS. 200U                                  3                1.75     1.03, 2.97       77.9       0.011
  **Hematuria**                                                                                              
  BTX-A 200U VS. Placebo                               5                1.59     0.97, 2.62       0          0.980
  BTX-A 300U VS. Placebo                               6                1.97     1.24, 3.13       0          0.984
  BTX-A 300U VS. 200U                                  6                1.22     0.83, 1.80       0          0.902

NA, Not available.

###### 

Summary of results with different dosage at different observation points for IOAB.

  Outcomes                              Number of RCTs   MD/RR   95%CI            I^2^ (%)   P for I^2^
  ------------------------------------- ---------------- ------- ---------------- ---------- ------------
  **Maximum Detrusor Pressure (MDP)**                                                        
  **12 weeks**                                                                               
  BTX-A 50U VS. Placebo                 1                4.7     -3.49, 12.89     NA         NA
  BTX-A 100U VS. Placebo                1                0.2     -7.55, 7.95      NA         NA
  BTX-A 150U VS. Placebo                1                -4.2    -12.70, 4.30     NA         NA
  BTX-A 200U VS. Placebo                1                5.7     -3.28, 14.68     NA         NA
  BTX-A 300U VS. Placebo                1                0.1     -9.86, 10.06     NA         NA
  BTX-A 100U VS. 50U                    1                -4.5    -11.78,2.78      NA         NA
  BTX-A 150U VS. 50U                    1                -8.9    -16.98, -0.82    NA         NA
  BTX-A 150U VS. 100U                   1                -4.4    -12.03, 3.23     NA         NA
  BTX-A 200U VS. 50U                    1                1       -7.57,9.57       NA         NA
  BTX-A 200U VS. 100U                   1                5.5     -2.66, 13.66     NA         NA
  BTX-A 200U VS. 150U                   1                9.9     1.03, 18.77      NA         NA
  BTX-A 300U VS. 50U                    1                -4.6    -14.20, 5.00     NA         NA
  BTX-A 300U VS. 100U                   1                -0.1    -9.33, 9.13      NA         NA
  BTX-A 300U VS. 150U                   1                4.3     -5.57, 14.17     NA         NA
  BTX-A 300U VS. 200U                   1                -5.6    -15.88, 4.68     NA         NA
  **36 weeks**                                                                               
  BTX-A 50U VS. Placebo                 1                2.6     -8.24, 13.44     NA         NA
  BTX-A 100U VS. Placebo                1                8       -2.52, 18.52     NA         NA
  BTX-A 150U VS. Placebo                1                3.4     -7.14, 13.94     NA         NA
  BTX-A 200U VS. Placebo                1                3.8     -6.66, 14.26     NA         NA
  BTX-A 300U VS. Placebo                1                8.1     -3.15, 19.35     NA         NA
  BTX-A 100U VS. 50U                    1                5.4     -1.62,12.42      NA         NA
  BTX-A 150U VS. 50U                    1                0.8     -6.25, 7.85      NA         NA
  BTX-A 150U VS. 100U                   1                -4.6    -11.15, 1.95     NA         NA
  BTX-A 200U VS. 50U                    1                1.2     -5.73,8.13       NA         NA
  BTX-A 200U VS. 100U                   1                -4.2    -10.62, 2.22     NA         NA
  BTX-A 200U VS. 150U                   1                0.4     -6.05, 6.85      NA         NA
  BTX-A 300U VS. 50U                    1                5.5     -2.58,13.58      NA         NA
  BTX-A 300U VS. 100U                   1                0.1     -7.55, 7.75      NA         NA
  BTX-A 300U VS. 150U                   1                4.7     -2.97, 12.37     NA         NA
  BTX-A 300U VS. 200U                   1                4.3     -3.26, 11.86     NA         NA
  **Detrusor compliance (DC)**                                                               
  **12 weeks**                                                                               
  BTX-A 50U VS. Placebo                 1                65.5    23.24, 107.76    NA         NA
  BTX-A 100U VS. Placebo                1                85.8    41.31, 130.29    NA         NA
  BTX-A 150U VS. Placebo                1                36.4    -8.85, 81.65     NA         NA
  BTX-A 200U VS. Placebo                1                104.5   47.52, 161.48    NA         NA
  BTX-A 300U VS. Placebo                1                75.8    23.42, 128.18    NA         NA
  BTX-A 100U VS. 50U                    1                20.3    -28.92, 69.52    NA         NA
  **Maximum Detrusor Pressure (MDP)**                                                        
  BTX-A 150U VS. 100U                   1                -49.4   -101.21, 2.41    NA         NA
  BTX-A 200U VS. 50U                    1                39      -21.74, 99.74    NA         NA
  BTX-A 200U VS. 100U                   1                18.7    -43.62, 81.02    NA         NA
  BTX-A 200U VS. 150U                   1                68.1    5.24, 130.96     NA         NA
  BTX-A 300U VS. 50U                    1                10.3    -46.15, 66.75    NA         NA
  BTX-A 300U VS. 100U                   1                -10     -68.14, 48.14    NA         NA
  BTX-A 300U VS. 150U                   1                39.4    -19.32, 98.12    NA         NA
  BTX-A 300U VS. 200U                   1                -28.7   -96.87, 39.47    NA         NA
  **36 weeks**                                                                               
  BTX-A 50U VS. Placebo                 1                60.3    16.08, 104.52    NA         NA
  BTX-A 100U VS. Placebo                1                39.3    -6.18, 84.78     NA         NA
  BTX-A 150U VS. Placebo                1                24.8    -30.63, 80.23    NA         NA
  BTX-A 200U VS. Placebo                1                64.8    4.24, 125.36     NA         NA
  BTX-A 300U VS. Placebo                1                60.8    11.64, 109.96    NA         NA
  BTX-A 100U VS. 50U                    1                -21     -62.98, 20.98    NA         NA
  BTX-A 150U VS. 50U                    1                -35.5   -88.10, 17.10    NA         NA
  BTX-A 150U VS. 100U                   1                -14.5   -68.16, 39.16    NA         NA
  BTX-A 200U VS. 50U                    1                4.5     -53.48, 62.48    NA         NA
  BTX-A 200U VS. 100U                   1                25.5    -33.45, 84.45    NA         NA
  BTX-A 200U VS. 150U                   1                40      -26.93, 106.93   NA         NA
  BTX-A 300U VS. 50U                    1                0.5     -45.43, 46.43    NA         NA
  BTX-A 300U VS. 100U                   1                21.5    -25.65, 68.65    NA         NA
  BTX-A 300U VS. 150U                   1                36      -20.81, 92.81    NA         NA
  BTX-A 300U VS. 200U                   1                -4      -65.83, 57.83    NA         NA
  **Adverse Events\***                                                                       
  **Urinary tract infections (UTI)**                                                         
  BTX-A 50U VS. Placebo                 2                1.95    0.96, 3.98       0          0.675
  BTX-A 100U VS. Placebo                5                2.55    2.09, 3.12       0          0.656
  BTX-A 150U VS. Placebo                2                2.36    1.19, 4.68       0          0.355
  BTX-A 200U VS. Placebo                2                2.68    1.46, 4.93       0          0.634
  BTX-A 300U VS. Placebo                1                2.12    0.98, 4.58       NA         NA
  BTX-A 100U VS. 50U                    2                0.97    0.59, 1.59       18.5       0.268
  BTX-A 150U VS. 50U                    2                1.24    0.78, 1.98       0          0.594
  BTX-A 150U VS. 100U                   2                1.29    0.81, 2.05       0          0.443
  BTX-A 200U VS. 50U                    1                1.42    0.89, 2.25       NA         NA
  BTX-A 200U VS. 100U                   3                1.44    0.94, 2.20       0          0.685
  BTX-A 200U VS. 150U                   1                1.09    0.72, 1.67       NA         NA
  BTX-A 300U VS. 50U                    1                1.02    0.61, 1.71       NA         NA
  BTX-A 300U VS. 100U                   1                0.95    0.57, 1.57       NA         NA
  BTX-A 300U VS. 150U                   1                0.79    0.49, 1.27       NA         NA
  BTX-A 300U VS. 200U                   1                0.72    0.45, 1.14       NA         NA
  **Urinary retention**                                                                      
  BTX-A 50U VS. Placebo                 1                3.84    0.47, 31.67      NA         NA
  BTX-A 100U VS. Placebo                4                13.99   5.71, 34.30      0          0.946
  BTX-A 150U VS. Placebo                1                12.04   1.65, 87.85      NA         NA
  BTX-A 200U VS. Placebo                1                9.92    1.34, 73.29      NA         NA
  BTX-A 300U VS. Placebo                1                10.95   1.50, 80.00      NA         NA
  BTX-A 100U VS. 50U                    1                2.04    0.74, 5.57       NA         NA
  BTX-A 150U VS. 50U                    1                3.14    1.22, 8.09       NA         NA
  BTX-A 150U VS. 100U                   1                1.54    0.75, 3.15       NA         NA
  BTX-A 200U VS. 50U                    1                2.58    0.98, 6.84       NA         NA
  BTX-A 200U VS. 100U                   2                1.34    0.66, 2.72       0          0.707
  BTX-A 200U VS. 150U                   1                0.82    0.42, 1.60       NA         NA
  BTX-A 300U VS. 50U                    1                2.85    1.10, 7.38       NA         NA
  BTX-A 300U VS. 100U                   1                1.4     0.68, 2.88       NA         NA
  BTX-A 300U VS. 150U                   1                0.91    0.48, 1.71       NA         NA
  BTX-A 300U VS. 200U                   1                1.1     0.56, 2.16       NA         NA
  **PVR-related catheterization**                                                            
  BTX-A 50U VS. Placebo                 2                1.06    0.26, 4.27       56.5       0.129
  BTX-A 100U VS. Placebo                2                2.31    0.72, 7.37       58.2       0.122
  BTX-A 150U VS. Placebo                2                2.4     0.79, 7.30       83.8       0.013
  BTX-A 200U VS. Placebo                3                15.74   3.13, 79.31      0          0.985
  BTX-A 300U VS. Placebo                1                14.93   0.89, 249.52     NA         NA
  BTX-A 100U VS. 50U                    2                2.28    0.73, 7.10       0          0.767
  BTX-A 150U VS. 50U                    2                2.89    0.98, 8.48       7.5        0.298
  BTX-A 150U VS. 100U                   3                1.22    0.57, 2.63       25.7       0.26
  BTX-A 200U VS. 50U                    1                3.95    1.17, 13.37      NA         NA
  BTX-A 200U VS. 100U                   1                1.94    0.77, 4.86       NA         NA
  BTX-A 200U VS. 150U                   1                1.06    0.49, 2.77       NA         NA
  BTX-A 300U VS. 50U                    1                3.05    0.87, 10.69      NA         NA
  BTX-A 300U VS. 100U                   1                1.5     0.57, 3.93       NA         NA
  BTX-A 300U VS. 150U                   1                0.82    0.36, 1.85       NA         NA
  BTX-A 300U VS. 200U                   1                0.77    0.35, 1.71       NA         NA
  **Hematuria**                                                                              
  BTX-A 100U VS. Placebo                2                1.38    0.78, 2.42       73.7       0.051

NA, Not available.

Effectiveness {#s8_3}
-------------

### Episodes of Urinary Incontinence (UI) Per Week {#s8_3_1}

#### For NDO in Short-Term Observation Period {#s8_3_1_1}

At 2 weeks. Only one study ([@B10]) reported this outcome, and the BTX-A (200U) showed a significant improvement in reducing episodes of UI per week (MD = -9.10, 95% CI: -14.10, -4.10) compared to placebo. However, no significant effect was obtained in BTX-A (300U) compared to placebo (MD = -6.10, 95% CI: -12.54, 0.34). In addition, no significant effect between BTX-A at 300U and 200U was observed (MD = 3.00, 95% CI: -3.30, 9.30) ([**Figure 2**](#f2){ref-type="fig"}).

![Forest plot of the changes of UI episodes per week of NDO at 2 weeks.](fphar-10-01618-g002){#f2}

At 6 weeks. Four studies ([@B10]; [@B21]; [@B28]; [@B41]) investigated these outcomes. [**Figure 3**](#f3){ref-type="fig"} demonstrated that the BTX-A 300U (MD = -11.42, 95% CI: -13.91, -8.93) and BTX-A 200U (MD = -10.72, 95% CI: -13.40, -8.04) were significantly decreased the episodes of UI compared to placebo, nevertheless, the effect between BTX-A 300U and 200U (MD = -0.38, 95% CI: -2.60, 1.84) showed no significant reduction in episodes of UI ([**Table 3**](#T3){ref-type="table"})

![Forest plot of the changes of UI episodes per week of NDO at 6 weeks.](fphar-10-01618-g003){#f3}

At 12 weeks. There was only one study ([@B10]) reported this outcome. [**Figure 4**](#f4){ref-type="fig"} showed that the effect from different dosages of BTX-A were significantly different compared to placebo (200U: MD = -8.50, 95% CI: -14.46, -2.54 and 300U: MD = -7.80, 95% CI: -13.73, -1.87), furthermore, no significant difference between 300U and 200U was observed (MD = 0.70, 95%CI: -4.73, 6.13) ([**Table 3**](#T3){ref-type="table"}).

![Forest plot of the changes of UI episodes per week of NDO at 12 weeks.](fphar-10-01618-g004){#f4}

### Maximum Detrusor Pressure (MDP) {#s8_3_2}

#### MDP for NDO in Short-Term Observation Period {#s8_3_2_1}

At 6 weeks. Five included studies ([@B46]; [@B10]; [@B21]; [@B20]; [@B41]) reported this outcome. Compared with placebo, BTX-A at both 300U (MD = -31.31, 95% CI: -35.79, -26.84) and 200U (MD = -33.01, 95% CI: -37.75, -28.27) showed a significant effect in reducing MDP for NDO patients. However, the effect of different dosages from BTX-A was not significant (300U versus 200U: MD = 1.16, 95% CI: -3.29, 5.60) ([**Figure 5**](#f5){ref-type="fig"}).

![Forest plot of the changes of MDP of NDO at 6 weeks.](fphar-10-01618-g005){#f5}

#### MDP for IOAB in Short-Term Observation Period {#s8_3_2_2}

At 6 weeks. There was only one study ([@B42]) investigated this outcome. And no significant effect between different dosages (50U, 100U, 150U, 200U and 300U) was observed compared to placebo. In addition, statistic difference was merely obtained in two subgroups (BTX-A 150U vs. 50U: MD = -8.90, 95% CI: -16.98, -0.82 and BTX-A 200U vs. 150U: MD = 9.90, 95% CI: 1.03, 18.77), meanwhile, the other remaining results showed no statistical difference ([**Figure 6**](#f6){ref-type="fig"}).

![Forest plot of the changes of MDP of IOAB at 12 weeks.](fphar-10-01618-g006){#f6}

#### MDP for IOAB in Long-Term Observation Period {#s8_3_2_3}

At 36 weeks. Only one study ([@B42]) reported the outcome. No significant difference was observed in neither different dosages at BTX-A (50U, 100U, 150U, 200U, and 300U) nor compared to placebo in IOAB patients ([**Figure 7**](#f7){ref-type="fig"}).

![Forest plot of the changes of MDP of IOAB at 36 weeks.](fphar-10-01618-g007){#f7}

#### PVR for NDO in Short-Term Observation Period {#s8_3_2_4}

At 2 weeks. Two included studies ([@B10]; [@B41]) investigated the outcomes. [**Table 3**](#T3){ref-type="table"} showed that BTX-A (200U: MD = 93.87, 95% CI: 63.91, 123.84; and 300U: MD = 178.22, 95% CI: 138.50, 217.95) significantly increased PVR compared to placebo. Furthermore, significant difference was also observed in BTX-A 300U versus 200U (MD = 84.13, 95% CI: 35.74, 132.51) ([**Table 3**](#T3){ref-type="table"}).

### Detrusor Compliance (DC) {#s8_3_3}

#### DC for NDO in Short-Term Observation Period {#s8_3_3_1}

At 6 weeks. Two included studies ([@B10]; [@B41]) reported this outcomes. [**Table 3**](#T3){ref-type="table"} showed that BTX-A groups (200U and 300U) significantly increased DC compared to placebo (200U: MD = 66.29, 95% CI: 44.24, 88.34; 300U: MD = 56.51, 95% CI: 35.00, 78.03). However, no significant difference was obtained in different dosages of BTX-A (300U vs. 200U: MD = -9.79, 95% CI: -35.00, 15.42) ([**Table 3**](#T3){ref-type="table"}).

#### DC for IOAB in Short-Term Observation Period {#s8_3_3_2}

At 12 weeks. There was only one study ([@B42]) reported this outcome. All of the subgroups showed no significant difference (BTX-A 50U vs. Placebo, MD = 65.50, 95% CI: 23.24, 107.76; 100U vs. Placebo, MD = 85.80, 95% CI: 41.31, 130.29; 200U vs. Placebo, MD:104.50, 95% CI: 47.52, 161.48; 300U vs. Placebo, MD = 75.80, 95% CI: 23.42, 128.18; 200U vs. 150U, MD = 68.10, 95% CI: 5.24, 130.96; 150U vs. Placebo, MD:36.40, 95% CI: -8.85, 81.65) ([**Table 4**](#T4){ref-type="table"}).

#### DC for IOAB in Long-Term Observation Period {#s8_3_3_3}

At 36 weeks. There was only one included study ([@B42]) reported this outcome. Statistically significant difference was observed in three subgroups (BTX-A 50U vs. Placebo, MD = 60.30, 95% CI: 16.08, 104.52; BTX-A 200U vs. Placebo, MD = 64.80, 95% CI: 4.24, 125.36; BTX-A 300U vs. Placebo, MD = 60.80, 95% CI: 11.64, 109.96). However, no significant difference was observed in other subgroups ([**Table 4**](#T4){ref-type="table"}).

Safety {#s8_4}
------

All of the effects on adverse events in NDO and IOAB patients were shown in [**Table 3**](#T3){ref-type="table"} and [**Table 4**](#T4){ref-type="table"}, respectively.

### Urinary Tract Infections (UTI) {#s8_4_1}

#### UTI for NDO {#s8_4_1_1}

Seven included studies ([@B46]; [@B10]; [@B24]; [@B21]; [@B20]; [@B41]; [@B7]) reported the UTI events in NDO patients. And significant effect on increasing UTI was observed in BTX-A 200U (RR = 1.44, 95% CI: 1.27, 1.62) and 300U (RR = 1.51, 95% CI: 1.35, 1.70), compared to placebo. Nevertheless, no significant effect was obtained between BTX-A 300U and 200U (RR = 1.07, 95% CI: 0.97, 1.18) ([**Table 3**](#T3){ref-type="table"}).

#### UTI for IOAB {#s8_4_1_2}

Eight included studies ([@B5]; [@B15]; [@B3]; [@B14]; [@B6]; [@B37]; [@B47]; [@B1]) reported this outcome. Four of 15 subgroups showed a significant effect on increasing UTI, compared to placebo (BTX-A 100U: RR = 2.55, 95% CI: 2.09, 3.12; 150U: RR = 2.36, 95% CI: 1.19, 4.68; 200U: RR = 2.68, 95% CI: 1.46, 4.93; 300U: RR = 2.12, 95% CI: 0.98, 4.58). And no significant difference was observed in the remain 11 subgroups ([**Table 4**](#T4){ref-type="table"}).

### Urinary Retention {#s8_4_2}

#### Urinary Retention of NDO {#s8_4_2_1}

Four included studies ([@B10]; [@B21]; [@B20]; [@B41]) reported available data of this outcome. Significant effect of BTX-A at 200U and 300U was observed compared to placebo (RR = 5.85, 95% CI: 3.84, 8.91; RR = 6.78, 95% CI: 4.46, 10.30). Nevertheless, the effect between BTX-A 300U and 200U didn't reach significance (RR = 1.16, 95% CI: 0.95, 1.43) ([**Table 3**](#T3){ref-type="table"}).

#### Urinary Retention of IOAB {#s8_4_2_2}

Four included studies ([@B15]; [@B6]; [@B37]; [@B47]) reported this outcome. And in 6 of 15 subgroups, BTX-A demonstrated a significant effect on increasing urinary retention (BTX-A 100U vs. Placebo: RR = 13.99, 95% CI: 5.71, 34.30; 150U vs. Placebo: RR = 12.04, 95% CI: 1.65, 87.85; 200U vs. Placebo: RR = 9.92, 95% CI: 1.34, 73.29; 300U vs. Placebo: RR = 10.95, 95% CI: 1.50, 80.00; 150U vs. 50U: RR = 3.14, 95% CI: 1.22, 8.09; 300U vs. 50U: RR = 2.85, 95% CI: 1.10, 7.38) ([**Table 4**](#T4){ref-type="table"}).

### Hematuria {#s8_4_3}

#### Hematuria of NDO {#s8_4_3_1}

Seven included studies ([@B46]; [@B10]; [@B24]; [@B21]; [@B20]; [@B41]; [@B7]) reported this outcome. The significant difference was only observed in BTX-A 300U, compared to placebo (RR = 1.97, 95% CI: 1.24, 3.13). For the others, no significant difference was observed (BTX-A 200U vs. Placebo: RR = 1.59, 95% CI: 0.97, 2.62 and 300U vs. 200U: RR = 1.22, 95% CI: 0.83, 1.80) ([**Table 3**](#T3){ref-type="table"}).

#### Hematuria of IOAB {#s8_4_3_2}

Two included studies ([@B6]; [@B47]) reported this outcome. Nevertheless, no significant effect was observed in BTX-A 100U compared to placebo (RR = 1.38, 95% CI: 0.78, 2.42) ([**Table 4**](#T4){ref-type="table"}).

### PVR-Related Catheterization of IOAB {#s8_4_4}

Five included studies ([@B43]; [@B5]; [@B9]; [@B15]; [@B14]; [@B37]) reported the available data for PVR-related catheterization in IOAB patients. Significant effect was observed in 2 of 15 subgroups (BTX-A 200U vs. Placebo: RR = 15.74, 95% CI: 3.13, 79.31; BTX-A 200U vs. 50U: RR = 3.95, 95% CI: 1.17, 13.37). And the effect of remain 13 subgroups didn't reach significance ([**Table 4**](#T4){ref-type="table"}).

### Muscle Weakness of NDO {#s8_4_5}

Four included studies ([@B10]; [@B24]; [@B21]; [@B41]) reported the available data for muscle weakness in NDO patients. Significant effect on increasing muscle weakness in BTX-A at 300U was observed compared to placebo (RR = 3.01, 95% CI: 1.50, 6.02), however, the effect of BTX-A at 200U was not significant (RR = 1.53, 95% CI: 0.76, 3.06). Furthermore, the effect of 300U was statistic significant compared to 200U (RR = 1.75, 95% CI: 1.03, 2.97) ([**Table 3**](#T3){ref-type="table"}).

Discussion {#s9}
==========

Based on the American Urological Association (AUA) guidelines ([@B22]) for management of OAB patients, the standard treatment, including education, behavior therapies, pharmacotherapy, and BTX-A, has been widely used for OAB ([@B17]; [@B52]; [@B30]). We performed this meta-analysis with the most up-to-date and comprehensive evidence for evaluating clinical benefit of BTX-A in UI in patients with NDO and IOAB. In order to reflect the effects more accurately, the different follow-up periods and dosages were analyzed. Ultimately, we found that the BTX-A demonstrated a significant effect on reducing episodes of UI and MDP in NDO patients, and BTX-A increased DC in IOAB patients, however, the adverse events in two groups increased in this meta-analysis.

Five kinds of dosages of BTX-A for NDO and IOAB (50U, 100U, 150U, 200U, and 300U) and placebo form 19 included studies considered as high quality under quality assessment were analyzed for evaluating the effectiveness. The results demonstrated that BTX-A 300U and 200U is superior to placebo in the protective role against UI episodes per week in NDO patients during follow-up period (2, 6, and 12 weeks), which was considered as a satisfactory outcome and enable BTX-A to be considered as intervention for management of UI. Furthermore, BTX-A reduced MDP during 6 weeks follow-up compared to placebo, which might account for the increase in PVR in both 200U and 300U, and the 300U was worse than 200U. The DC in NDO was increased at both BTX-A 200U and 300U, which might account for the reduction in episodes of UI. These results were consistent with other similar meta-analyses ([@B52]; [@B8]). However, the BTX-A 300U showed no superior effect on UI, MDP, and DC compared to 200U, with increased UTI, urinary retention, muscle weakness, and hematuria, thus, the BTX-A 300U was not recommended in management of UI in NDO patients in this study.

Furthermore, the results also revealed that dosages of BTX-A not less than 50U were superior to placebo in the improvement of DC in IOAB at 12 and 36 weeks, except the BTX-A 150U and 100U at 36 weeks and BTX-A 150U at 12 weeks in this study. This superior effect was consistent with the Rovner's study ([@B42]) which has reported that BTX-A at dosages of more than 100U showed significant improvement in OAB. It was also observed between BTX-A 200U and 300U for UI episodes per week at 2 weeks in NDO patients, which may be caused by small sample size. However, compared with placebo, five dosages of BTX-A demonstrated no significant difference in for MDP in IOAB at 12 and 36 weeks, which was not consistent with Chapple's study ([@B6]) reported OAB patients could be benefit from BTX-A 100U. In addition, BTX-A 200U and 300U had nearly same effectiveness on NDO and IOAB. Although Nuanthaisong's study ([@B38]) reported that BTX-A over 360U was an effective treatment, we mainly focused on dosages not more than 300, especially 300 and 200U for NDO and IOAB, thus, the studies exploring effect of dosages of BTX-A more than 300U are required in further research. All these results suggested that BTX-A 300U and 200U is superior to placebo in effectiveness on NDO at short-term observations, especially at 6 weeks. Remarkably, in consideration that UI was regarded as a chronic disease, and BTX-A 200U also contributed to increase DC in IOAB patients during 36 weeks, therefore, the researches exploring long-term effect of BTX-A are required in future.

Another essential part of this study was the assessment of safety of BTX-A, and we found that basically all the adverse events were increased in both NDO and IOAB patients in this meta-analysis. The results showed that possibility of suffering UTI was higher in both BTX-A 300U and 200U in NDO than placebo, but the BTX-A 300U was not higher than 200U. This effect might due to the markedly increased PVR and urinary retention. Therefore, the NDO patients treated with BTX-A must be aware of the potential risk of UTI, and the prophylactic antibiotics could be considered. These complications could account for the increased risk of hematuria as consequence, except in BTX-A 200U. And no effect on increasing risk of muscle weakness was observed in BTX-A 200U in NDO patients, however the BTX-A 300U significantly increased this risk compared to both placebo and BTX-A 200U. For IOAB patients, almost every dosages of BTX-A, except at 50U, demonstrated a higher risk of urinary retention compared to placebo. Furthermore, the increased dosages basically did not increase the risk of urinary retention. Therefore, in theory, the different dosages would not increase the risk of UTI as consequence, which was consistent with the results of this study that the risk of suffering UTI was higher than placebo, however, no increased risk was observed in different dosages. In addition, no requirement of PVR-related catheterizations was observed in IOAB patients compared to placebo, except at dosage of 200U. The exception and heterogeneity may be caused by small sample size. Although BTX-A was superior to placebo, indicating that BTX-A had slightly more adverse events than placebo. However, the localized urologic events, which considered as main adverse effects of BTX-A, were not found. It might due to the well-tolerated, however, more researches are still required in this field.

The advantages in this study are as follows. Firstly, Chinese articles were also reviewed in this meta-analysis as well as English studies, unfortunately, there were no studies met the inclusion criteria. Secondly, BTX-A at different dosages were investigated, and the clinical benefit of BTX-A was assessed based on comprehensive measurement of outcomes. Thus, the most up-to-date evidence has been provided for clinical practice and medical guidelines. Meanwhile, different dosages were evaluated to assess the safety. In our study, the results demonstrated that the increase of dosage of BTX-A has no protective effect of complications. For effectiveness, although the BTX-A has a protective effect for NDO, different dosage showed no significant discrepancy in UI episodes, MDP and DC, except PVR. For IOAB, the most remarkable outcome is the difference of PVR for injecting diverse dosage. In order to detail the long-term potential impact, we comprehensively and systematically evaluated BTX-A in treatment of UI in patients with NDO and IOAB for short- and long-term observation periods, which could reduce the risk of from correct outcomes as well. Although significant differences were not obtained in our study, we offered a potential possibility for other researcher to investigate this field for the prognosis of patients. Furthermore, results of subgroup analyses based on dosages and types of OAB objectively disclosure true the clinical benefit, and it has guiding clinicians to treat NDO and IOAB. After all, Surgery may be carried out as a last resort ([@B30]), resulting in trauma, thus the drug treatment of OAB requires urgent attention.

There are also several limitations in this study. Firstly, insufficient sample size and RCTs is the main disadvantages in our study, caused by the study design of original studies. For example, we excluded one study reported results 72 h after injection, which is possible to ignore the long-term impact which might produce the result of greater difference. Due to the limitations of language, the studies using other languages (except English and Chinese) were ignored. Secondly, benign prostatic hyperplasia (BPH) is a prominent factor, resulting OAB. The pathogenesis was failed to be executed using subgroup analyses, because of the lack of relevant data. The data of short-term and long-term observations periods were insufficient in assess the clinical benefits of BTX-A. Therefore, more high-quality larger RCTs with short-term and long-term observations periods should be added to assess of the clinical benefits of BTX-A from different perspectives.

Conclusion {#s10}
==========

This meta-analysis indicates that BTX-A 300U and 200U showed a positive effect on management of UI NDO for short-term therapy based on current evidence. In addition, clinical benefits were not found in BTX-A 50U, 100U, 150U, 200U, and 300U for IOAB for long-term treatment, except the efficacy of BTX-A for DC. There is a significant finding that dosages 300U and 200U could improve DC of IOAB for short- and long-term treatments, compared to placebo. Furthermore, BTX-A 300U and 200U have no significant difference in adverse events. Therefore, we recommend that BTX-A 200U could be considered as intervention for UI in patients with NDO for the short-term treatments, with minimal, local, and manageable adverse events. The long-term treatments of BTX-A for UI in NDO patients and short-term treatments for IOAB patients require more RCTs to be investigated.
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